• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A method of synthesizing nucleic acids, of great length, comprising at least one initial nucleic acid fragment elongation cycle, comprising a) a phase of enzymatic addition of nucleotides to said fragments, b) a phase of purification of the fragments having a correct sequence c) a possible phase of enzymatic amplification, each cycle being carried out in a reaction medium compatible with an enzymatic addition and amplification, such as an aqueous medium, the synthesis method also comprising at the end of the set of elongation cycles, a final stage of final amplification. Use of the method for the production of genes, or synthetic nucleic acid sequences, DNA or RNA. Kit for the implementation of the method.
    公开号:FR3020071A1
    申请号:FR1453455
    申请日:2014-04-17
    公开日:2015-10-23
    发明作者:Thomas Ybert；Sylvain Gariel
    申请人:DNA Script SAS；
    IPC主号:
    专利说明:

    [0001] The present invention relates to a method for synthesizing nucleic acids, in particular nucleic acids of great length as well as a kit for implementing this synthesis method. STATE OF THE ART Polymers of nucleic acids are currently synthesized in vitro by organic synthesis methods. The most common of these methods is the so-called phosphoramidite method described by Adams et al. (1983, J. Amer, Chem Soc 105: 661) and Froehler et al. (1983, Tetrahedron Lett 24: 3171). This method of synthesis is very widespread and remains the most commonly used by different laboratories and companies with nucleic acid production activities. By its degree of use and by its own performance, this method constitutes the current reference in terms of nucleic acid synthesis. This method implements a coupling reaction between the last nucleotide of a nucleic acid fragment and the nucleotide to be added. The first coupling reaction is between a solid support and the first nucleotide. Coupling takes place between the 5'-OH group of the last nucleotide of the nucleic acid and the 3'-OH group of the nucleotide to be added. In this way the synthesis of the nucleic acid is said to be of type 3 'to 5'. In the coupling reaction, the phosphoramidite group is involved in the reaction. Each nucleotide to be added is protected at the 5'-OH group so as to avoid uncontrolled polymerization of several nucleotides of the same type, the coupling step leading to the addition of a single nucleotide. Generally the protection of the 5'-OH group is carried out by a trityl group. In order to avoid possible degradation due to the use of strong reagents, nucleotide-borne bases may also be protected. Generally the protection used involves an isobutyryl group (Reddy et al., 1997, Nucleosides & Nucleotides 16: 1589). After each incorporation of new nucleotides the 5'-OH group of the last nucleotide of the chain undergoes a deprotection reaction so as to make it available for the next polymerization step. The bases carried by the nucleotides composing the nucleic acid, they are deprotected only after completion of the polymerization. Between each nucleotide addition step, a specific neutralization step is performed. It consists in permanently modifying the deprotected 5'-OH groups of the fragments which have not integrated a nucleotide at the coupling step and whose sequence is in fact incorrect. This step generally involves an acetylation reaction. Finally, an ultimate oxidation step (e.g., iodine treatment) is required to regenerate the naturally occurring phosphodiester linkage between the nucleotides of nucleic acid molecules. Organic nucleic acid synthesis methods, such as that discussed above, require large amounts of unstable, hazardous, expensive reagents that can impact the environment and health. The various steps implemented are also expensive and sometimes difficult to control. Finally, the devices making it possible to carry out these syntheses in a practical way are complex, require a large investment and must be operated by a qualified and dedicated workforce. One of the major disadvantages of these organic synthesis techniques is their low yield. During each cycle, the coupling reaction occurs only in 98 to 99.5% of the cases, leaving in the reaction medium nucleic acids that do not have a correct sequence. As the synthesis progresses, the reaction medium is therefore greatly enriched in fragments comprising a totally incorrect sequence. The deletion type errors that occur thus have particularly dramatic repercussions causing a shift in the reading frame of the nucleic acid fragments considered. Thus, for a correct coupling reaction in 99% of the cases, a nucleic acid comprising 70 nucleotides will be synthesized with a yield of less than 50%. This means that after 70 cycles of addition, the reaction medium will comprise more fragments having an erroneous sequence than fragments having a correct sequence. This mixture is then unsuitable for further use. In general, the proportion Z of correct fragments contained in the mixture after i addition cycles of nucleotides, each addition having a success rate p can be written: Z = pi add to the problems caused by the limit of Coupling efficiency of the same problems for all other reactions involved in the synthesis process. Indeed, these reactions are not always complete and also favor the creation of nucleic acid fragments having an erroneous sequence or a non-conforming molecular structure. These fragments swell the ranks of the impurities as and when the cycles of synthesis.
    [0002] The methods of organic synthesis of nucleic acid are therefore ineffective for the synthesis of long fragments because they generate a very large amount of fragments having an incorrect sequence, then considered as impurities. In practice, the maximum length of fragments that can be efficiently produced by these methods is between 50 and 100 nucleotides. There are alternative techniques using an enzymatic catalyst for carrying out the coupling step, in particular for enzymes that can carry out the coupling reaction between nucleotides in the absence of a template strand. Several polymerase type enzymes seem to be suitable for this kind of synthetic methods. Polymerase-type enzymes, or ligases, capable of creating a phosphodiester bond between two nucleotides, more particularly the enzymes of the family of telomerases, of the family of polymerase II-type transferase enzymes, or of the family of PNPases , the template-independent RNA polymerase family, the terminal transferase family or the ligase family are among the enzymes that can act as enzymatic catalysts. The enzyme RNA ligase is useful in this context, as well as the terminal deoxynucleotidyl transferase (TdT).
    [0003] These so-called enzymatic synthesis methods make it possible to dispense with the unstable, dangerous and expensive solvents and reagents used during organic synthesis methods. The enzymatic synthesis methods perform nucleic acid polymerization in the 5 'to 3' direction. Thus, the coupling takes place between the 3'-OH group of the last nucleotide and the 5'-OH group of the nucleotide to be added.
    [0004] In certain enzymatic methods, the enzyme allowing the polymerization is directly added to natural nucleotides (Deng et al 1983, Meth Enzymal 100: 96). From an initial nucleic acid fragment called a primer, the polymerization enzyme as well as nucleotides of the same type are added. The polymerization reaction is then initiated until it is stopped by a physical or chemical method. The nucleic acid grows sequentially by repeating these phosphodiester bonding steps. The use of natural nucleotides results in an uncontrolled polymerization phenomenon resulting in a very heterogeneous mixture of nucleic acid molecules. Indeed nothing prevents the addition of several nucleotides of the same type after a first addition. In practice such a synthetic method is found to be unusable for the synthesis of nucleic acid fragments having a desired sequence.
    [0005] The use of protected nucleotides makes it possible to a certain extent to solve this uncontrolled polymerization phenomenon, totally or partially preventing the creation of additional phosphodiester bonds with respect to that desired, and thus causing the synthesis to stop.
    [0006] A problem encountered in this case is that of the synthesis of protected nucleotides. The establishment of the protection that can be located on the base or on the 3'-OH group involves a succession of complex chemical reactions. At the end of the synthesis the nucleotides having the desired protection are rarely present in pure form. Certain impurities, such as unprotected starting nucleotides, have a very negative effect on the synthesis yields. Another problem encountered concerns the protection efficiency of the nucleotides. Depending on the strategy adopted, the protection effectiveness is sometimes insufficient to guarantee good synthesis yields. In this case, an effective strategy seems to be the total prevention of creation of a covalent bond between the terminal nucleotide and a present nucleotide. This usually results in the transformation of the 3'-OH group into another chemical function incapable of undergoing transformation by the enzyme.
    [0007] Another difficulty relates to the ability to deprotect the nucleotides, once the addition is made, satisfactorily and before the addition planned for the next cycle. Each nucleic acid fragment whose last nucleotide fails to be deprotected will not be able to accept the next nucleotide in the next cycle. This fragment will therefore have an erroneous sequence which has the effect of reducing the yield of the synthesis.
    [0008] A major problem encountered by enzymatic synthesis methods is the efficiency of the coupling reaction. Although superior to organic synthesis methods, the overall coupling efficiency of enzymatic methods is well below 100%. Thus, fragments that failed to add an additional nucleotide remain in the reaction. Indeed, the enzyme must be able to meet its substrates, a nucleic acid fragment on the one hand and a nucleotide on the other hand, in order to carry out the binding reaction. Since the enzyme and the nucleic acid fragment are macromolecules, they may sometimes not be present within the allotted time. A high concentration of enzyme and nucleic acid fragments makes it possible to minimize this phenomenon without however completely eliminating it. In contrast, methods involving successive additions of enzyme without a washing step or removal of excess reagents, promote too much dilution of the reagents resulting in low coupling efficiencies. Often, the appearance of fragments having an erroneous sequence, contributing to the lowering of the synthesis yield, results in the addition of a neutralization step. This step consists in eliminating the 3'-OH groups which have not formed a phosphodiester bond. This step can be carried out by chemical reaction or by the action of an enzyme, but it is not, in any case, on the one hand, not 100% effective, and on the other hand, it does not eliminate not the relevant fragments that contribute to the heterogeneity of the mixture.
    [0009] In some processes, after reaction, the introduced enzymes and reagents are inactivated by the addition of other enzymes or reagents or by the application of particular physical conditions. This strategy makes it possible to avoid the washing steps, but involves an inexorable increase in the reaction volume, which results in a dilution of the reagents and therefore a decrease in the efficiency and speed of the reactions involved as described above. In addition, this strategy does not allow the recycling of certain expensive reagents such as the polymerization enzyme for example. Finally, this strategy generates a number of consequent reaction waste resulting from the inactivation of the initial reagents. This waste also contributes to the heterogeneity of the final mixture as well as to the reduction of the synthesis yield by possible inhibitions of enzymes or reagents.
    [0010] Whatever the methods employed, a large number of impurities accumulate during synthesis cycles. The impurities consist mainly of fragments that do not have the expected nucleotide sequence. Several elimination strategies are available, such as size exclusion chromatography or polymer gel electrophoresis or solid phase fixation. However, the first has such low performance that it is not possible for the synthesis of fragments of more than ten nucleotides, the second assumes that the initial nucleic acid fragment is attached to a solid non-soluble support . Thus, at each cycle, simple steps of washing with solid support support allow the removal of all impurities, except the fixed nucleic acid fragments. Although extremely efficient, this strategy does not allow the elimination of fragments that have not been added nucleotides during a cycle, or those that have been neutralized. Thus the majority impurities are not eliminated which contributes to the significant decrease in the synthesis yield.
    [0011] To date, no method of nucleic acid synthesis is really satisfactory, and does not answer the problem of synthesis of long fragments regardless of their sequence. One of the primary reasons is the systematic yield loss inherent in all methods proposed to date. In particular, this loss of yield is dependent on the length of the desired nucleic acid and reaches proportions such that it prevents the synthesis of long fragments. Specifically, the direct synthesis of nucleic acid fragments of the typical size of a gene, between 500 and 5000 nucleotides, is completely inaccessible by current methods.
    [0012] A first object of the invention is to overcome the disadvantages of the methods of the prior art by proposing a nucleic acid synthesis process with a high yield.
    [0013] Another object of the invention is to provide a method for synthesizing nucleic acids of great length, that is to say of at least several hundreds or thousands of nucleotides. Another object of the invention is to propose a synthesis process comprising a succession of steps which, when combined, make it possible to maintain an extremely high synthesis yield and this independently of the size of the nucleic acid fragment to synthesize. SUMMARY OF THE INVENTION These objects are achieved by the process for synthesizing nucleic acids according to the present invention, in particular nucleic acids of great length, comprising at least one cycle of elongation of nucleic acid fragments, called fragments. initial, comprising n (or of sequence to n) nucleotides, each cycle being subdivided as follows: a) an enzymatic addition phase of Xi nucleotides at one end of said fragments, X being between 1 and 5, of preferably between 1 and 3, i being the number of the ring, making it possible to obtain fragments comprising n + Xi nucleotides, called the first phase, b) a purification phase of the fragments having a correct sequence comprising n + Xi nucleotides, called the second phase C) a possible phase of amplification, preferably enzymatic, such as by PCR, fragments having a correct sequence at n + Xi nucleotides, by a multiplying factor Yi, i being the ring number, Y may be between 1 and 4.1010, preferably between 1 and 1.109, called third phase, each cycle being carried out in a reaction medium compatible with an enzymatic addition and amplification, such as an aqueous medium, the synthesis method also comprising at the end of all the elongation cycles, a final amplification step of a multiplying factor Yf. Each addition phase by enzymatic catalysis is followed by a purification phase which makes it possible to keep in the reaction medium only the fragments of correct sequence comprising n + Xi nucleotides, and these are the only fragments that will be subjected to an optional amplification phase, either between each cycle, or after a given number of cycles, or only at the end of the elongation cycles, when the nucleic acid fragments have the desired length. The method of the present invention thus makes it possible to synthesize nucleic acid fragments having the desired sequence. It avoids the use of model nucleic acid fragments and allows the synthesis of products of very high purity, regardless of the length and nature of the chosen sequence.
    [0014] More particularly, the purification phase of the n + Xi nucleotide correct sequence fragments comprises the removal of the non-added fragments and / or any other unwanted residual reagent. The amplification phase is in particular a selective amplification of the correct sequence fragments with n + xi nucleotides, designated as fragments of correct sequence, multiplying in the reaction medium the fragments having a correct sequence by a multiplicative factor more than 10 times higher, preferably more than 100 times higher, the multiplicative factor of other fragments, called fragments of incorrect sequence, including non-added fragments.
    [0015] According to a preferred embodiment of the invention, the nucleic acid synthesis process comprises several cycles subdivided as follows: a) a first phase comprising the following successive stages: a first attachment step, on a first support, a first end of nucleic acid fragments initial or in the course of elongation, containing n nucleotides, a step of adding the reagents necessary for the enzymatic addition, a step of enzymatic addition of Xi nucleotides to the second end of said nucleic acid fragments, X being between 1 and 5, preferably between 1 and 3, i being the number of the ring, a possible step of eliminating the reaction medium from the unwanted reagents, - a step of stalling said first support of said fragments to n + Xi nucleotides, - a first step of transferring said fragments to n + Xi nucleotides; b) a second phase comprising the following successive steps: a second step of attachment, on a second support, of said fragments with n + Xi nucleotides by their end bearing the xi nucleotides added during the first phase, a step of removing the non-added fragments and non-hooked fragments on the second support; - a stalling step of said n + Xi nucleotide fragments of said second support - a possible step of removing the reaction medium from the residual unwanted reagents; c) an optional amplification phase comprising the following successive steps: a step of adding the reagents necessary for the amplification, a step (optionally composed of substeps allowing the process) of multiplying a multiplying factor Yi of the fragments to n + Xi nucleotides, i being the ring number, Y being between 1 and 4.1010, preferably between 1 and 1.109, - a step of transferring the fragments to n + Xi nucleotides. Preferably the first support has a surface on which are noncovalently attached strands of nucleic acids to at least three nucleotides, said nucleotides of these strands being complementary to the nucleotides present at the first end of the initial fragments, so to immobilize by hydrogen bonds between their respective bases, said first ends of the fragments.
    [0016] Said first and second supports are advantageously, in the form of a glass plate, a plate of polymer material, or beads, preferably one or other of these supports, advantageously the second support, having magnetic properties.
    [0017] The synthesis method according to the present invention is based on the use of enzymatic catalyst to achieve the phosphodiester bond for the polymerization of nucleotides component nucleic acid fragments to achieve. More specifically, the process implements, but is not limited to, enzymes for the creation of the phosphodiester bond between the 3'-OH group of the nucleic acid fragment being synthesized and the 5'-OH group of the nucleotide to be added during the enzymatic addition step. In a preferred embodiment, the enzymes used are capable of polymerizing the nucleotides independently of the presence of a template template. Such enzymes are then capable of synthesizing nucleic acids in the absence of any complementary strand in the medium. In addition, these enzymes have the ability to synthesize single-stranded nucleic acid fragments. The addition of X nucleotides is therefore advantageously carried out enzymatically, by means of enzymes able to polymerize modified nucleotides without the presence of a template strand. The enzyme is, for example, chosen from enzymes of the family of telomerases, of the family of translational enzymes, of the R1 polymerase type or of the family of PNPases, of the template-independent RNA polymerase family, of the family of 10 terminal transferases or the family of ligases, template-independent DNA polymerases or the enzymes of the family of terminal deoxynucleotidyl transferases (TdT). These enzymes are expressed by certain cells of living organisms and can be extracted from these cells or purified from recombinant cultures. These enzymes require the existence of an initial nucleic acid fragment called a primer. This initial fragment serves as a substrate during the first cycle of elongation of the nucleic acids to be synthesized. It has a free 3'-OH group to react with the 5'-OH group of the first nucleotide to be added. In a preferred embodiment, the primers have the most favorable length for carrying out the present invention as well as the most favorable sequence for the success of the successive steps. If necessary, several different primers can be used simultaneously or successively without limitation of number. This primer can comprise natural nucleotides or modified nucleotides. Nucleotides employed generally consist of a cyclic sugar having at least one chemical group at the 5 'end and a chemical group at the 3' end and a natural or modified nitrogen base. The conditions of the reaction medium, in particular the temperature, the pressure, the pH, an optional buffered medium, and other reagents, are chosen to allow optimal operation of the polymerization enzymes while guaranteeing the integrity of the molecular structures of the various reagents as well. present. The free end of the nucleotide or nucleotides added to the fragments advantageously comprises a protective chemical group, to prevent a multiple addition of the X nucleotides on the same fragment. The addition of protected nucleotides at their 3 'end is one of the preferred embodiments of the present invention, the protective group intended to prevent any possibility of subsequent polymerization thus limiting the risk of uncontrolled polymerization. In addition to preventing the creation of a phosphodiester bond, other functions, such as the interaction with one of the supports or the interaction with other reactants of the reaction medium can be attributed to said protective group.
    [0018] For example, the second support may be covered with molecules, such as proteins, allowing a non-covalent bond between these molecules and said protective chemical group, and thus the immobilization of the fragments added during the second attachment step.
    [0019] The stalling step of said n + Xi nucleotide fragments of said second support can then be carried out by modifying the conditions of the reaction medium, such as changes in pH or temperature, or under the action of electromagnetic radiation if said second medium is a magnetic medium.
    [0020] Preferably, the first attachment step corresponds to the attachment of the 5 'ends of the starting nucleic acid fragments, or being elongated, and the second attachment step corresponds to the attachment of the 3' ends. said n + Xi nucleotide fragments.
    [0021] The enzymatic addition is advantageously carried out in the 5 'to 3' direction. After the purification step, the deprotection is necessary for the good progress of the synthesis. Its function is to regenerate, at the 3 'end, an -OH group capable of reacting during the next polymerization phase, and thus to allow subsequent elongation, during the next i + 1 cycle, of nucleic acid fragments of sequence n + Xi protected end. The deprotection step of said end may in particular implement a chemical reaction, an electromagnetic interaction, an enzymatic reaction and / or a chemical or protein interaction.
    [0022] The present invention advantageously implements an orthogonal synthesis mode. In this mode of synthesis some reagents have properties that allow them to not undergo certain steps while the other reagents will suffer. This mode of synthesis is particularly suitable for the present invention.
    [0023] The starting nucleic acid fragment primers thus have functionalities at their 5 'ends allowing them to interact with solid supports or elements immobilized on said supports. The functions of the primers are preserved during the course of the synthesis. The interactions are reversible in particular by application of specific physicochemical conditions. It is also possible to irreversibly neutralize these interaction characteristics by chemical or enzymatic reaction. The primers are the starting point of the synthesis by receiving the first nucleotide to be added. They are preserved during this same synthesis until the addition of the last nucleotide present in the desired sequence. The functionalities present on the 5 'end of these primers are advantageously chosen so as to remain functional throughout the synthesis. Consequently, these functionalities confer on the nucleic acid fragments being elongated the same characteristics and properties as those initially conferred on the primers, in particular, in the preferred embodiment of the invention, the ability to cling when of each elongation cycle, at the first solid support, prior to the enzymatic addition step, via nucleic acid strands already attached to said first support.
    [0024] In the preferred embodiment of the invention, the functionalities present at the 5 'end of the primers used for the initiation of synthesis allow non-covalent interactions with molecules or proteins present on said first solid support. During each step of the synthesis, these functionalities are preserved because they have no reactivity with the reagents used. The non-covalent bonds being sufficiently strong to ensure stable interactions under certain physicochemical conditions but also sufficiently weak to be removed in case of application of different physicochemical conditions. Finally, the molecular structure of these functionalities may give them the possibility of being destroyed or removed by the action of specific reagents, this property being useful in cases where it is desired to destroy or delete the nucleotides constituting the initial primers. The surfaces of said solid supports have functionalities enabling them to interact with the functionalities present on the primers. Like the latter, the functionalities of these solid supports must be able to undergo the various stages of the synthesis cycle without degradation of their interaction performance. The application of certain physicochemical conditions such as temperature, pH and / or electromagnetic field variation may make it possible to put an end to the existing interactions between the nucleic acid fragments being synthesized and the solid supports. In other cases the application of physicochemical conditions distinct from those described above should allow a strengthening of these interactions. The different physicochemical conditions are applied at the appropriate times of synthesis cycles of the nucleic acid fragments. More particularly, physicochemical conditions enhancing the interactions between the solid supports and the 5 'ends of the fragments are applied during all the synthesis steps except during the stall steps of the nucleic acid fragments. During these stall steps, the physicochemical conditions are modified in order to release the fragments. Between two phases of each cycle of elongation, the nucleic acid fragments detached from the supports are moved by creating a mobile fluid stream, by means of pumps or any other device for moving fluids. More particularly, the fragments are then detached from said supports by a flow of liquid providing the physicochemical conditions favorable to the cancellation of the interaction between the nucleic acid fragments and said supports. The fragments are then displaced while the supports remain immobilized.
    [0025] The added nucleotides constitute the elementary polymerization entities of the synthesis. They are added one after the other to the nucleic acid fragments. These nucleotides have interaction features in addition to their link reactivity functionality and their protection features. The nucleotide interaction functionalities function similar to the interaction functionalities of the 5 'end of the primers.
    [0026] Preferably, the interaction functionalities of the 5 'end of the nucleic acid fragments being synthesized and those of the newly added nucleotides are used jointly during the same synthesis cycle.
    [0027] The application of specific physicochemical conditions such as temperature, pH, the electromagnetic environment or the presence of filtration equipment can be implemented to achieve the separation between the different supports mentioned above and the fragments of nucleic acids of correct or incorrect sequence. The various steps of the enzymatic synthesis of nucleic acid fragments according to the invention contribute to the performances of this synthesis by ensuring the correct polymerization of a maximum of nucleic acid fragments, and also allow, via the mechanisms of previously mentioned interaction, the elimination of the largest possible number of nucleic acid fragments not having the desired sequence because having failed at one of the steps constituting the elongation cycle.
    [0028] Thus, the present invention implements the principle of "wide elimination" of nucleic acid fragments. This "wide elimination" mainly encompasses fragments having an erroneous sequence but also to a certain extent fragments having a correct sequence. The purpose of this concept of wide elimination is to eliminate all the fragments having an erroneous sequence even if this is done to the detriment of the conservation of certain fragments having a correct sequence. In general, the impurity removal steps, including in certain cases the fragments having an erroneous sequence, are carried out by washes, using mobile fluid flows. During the washing steps the elements that should be preserved are particularly by interaction with solid supports, for example held immobile or retained by filtration. Preferably, in the process according to the present invention, the interactions are selected so as to be selective and therefore to act only on the nucleic acids with a correct sequence and not on the other compounds present in the reaction medium such as for example unreacted nucleic acid fragments, enzymes or buffer solution components. By way of example, the interactions between the added nucleotides and the solid supports are chosen so that only the fragments having incorporated the protected nucleotides are preserved during the washing steps. These same interactions are chosen so as to be sufficiently weak so that in all cases only the fragments having incorporated the protected nucleotides are preserved during the washing steps. Such weak interactions may result in not keeping, to a certain extent, the fragments having well incorporated the nucleotides even if they were to be preserved. This characteristic is sought for the application of the method according to the invention insofar as it ensures the most complete elimination possible unwanted nucleic acid fragments. The non-covalent interactions previously described are chosen so that they allow an effective interaction with a proportion of the desired fragments and a zero interaction with the unwanted fragments, in particular by optimizing the structure of the interacting entities and optimizing the conditions. physico-chemical responsible for the interaction. By way of nonlimiting example, the non-covalent interactions used in the context of the various chromatography or affinity purification techniques allow such performances. The synthesis method which is the subject of the present invention is also particularly suitable for the simultaneous synthesis of nucleic acid fragments. A synthetic cycle allowing the increase of a nucleotide of the desired sequence can be divided into several steps that can be carried out in parallel for the simultaneous synthesis of several different fragments. Thus, subject to sufficient resources, there is no limitation to the numbers of different nucleic acid fragments that can be simultaneously synthesized.
    [0029] Advantageously, the parallel synthesis of numerous fragments can significantly increase the nucleic acid synthesis capabilities of an experimenter embodying the present invention. In a preferred embodiment of the present invention, in parallel with the synthesis of the desired fragments, it can effect the simultaneous synthesis of all or part of the complementary fragments to those desired.
    [0030] In another preferred embodiment, syntheses can be carried out simultaneously on fragments having a link between them. By way of example, the subject fragments may be portions of a larger sequence of interest such as, but not limited to, a gene, a chromosomal region, a chromosome or a genome. Still as an example, these different fragments constituting a common sequence may have identical or complementary portions of sequence facilitating a possible subsequent assembly.
    [0031] The method according to the present invention includes one or more phases of amplification of the nucleic acid fragments of correct sequence, making it possible to multiply the number of these nucleic acid fragments present in the reaction medium. This nucleic acid chain amplification utilizes an enzymatic polymerization method combining template nucleic acid strands, nucleotides, complementary initial primers, and template-dependent polymerization enzymes. The result of the amplification consists of a large number of copies of the matrix strands initially present. The amplification is performed by a succession of steps constituting an amplification cycle. The multiplication factor YM of the amplified fragments is dependent on the number of amplification m cycles carried out according to the formula: YM = 2 m In a preferred embodiment, the enzymes used for the amplification are capable of ensuring the nucleotide polymerization by copy. of the matrix strand. Such enzymes are then dependent on a complementary strand. These enzymes have the ability to synthesize double-stranded nucleic acid fragments. Nonlimiting examples for the present invention of enzymes that can be used for the amplification phase are DNA-dependent DNA polymerases. These enzymes are commercially available and are often purified from recombinant cultures. The nucleotides employed for the amplification are generally natural nucleotides comprising at least one chemical group at the 5 'end of the triphosphate type and a chemical group at the 3' end of the hydroxy type and of a natural nitrogenous base. In a preferred embodiment, the nucleotides employed for amplification are naturally occurring nucleotides.
    [0032] The reaction conditions such as temperature, pressure, pH, buffer, cofactors and / or other reagents, as well as the steps and their sequence are chosen so as to ensure optimal amplification of the fragments in question.
    [0033] The amplification requires the presence of primers complementary to the nucleic acid fragments to be amplified. The complementary primers are short length nucleic acid fragments having a nucleotide sequence complementary to that of the fragments to be amplified. They are therefore composed of similar nucleotides and can interact with those constituting the fragments to be amplified. These complementary primers can advantageously be synthesized in parallel with the nucleic acid fragments synthesized according to the method of the present invention. Thus it is possible according to this principle to amplify any sequence considered without using any method different from that of the present invention. The complementary primers must interact noncovalently with one of the ends of the fragments to be amplified so that the amplification enzyme can react. These non-covalent interactions are dependent and specific for the complementary sequences of the fragments to be amplified and the primers. Thus the specificity of these interactions greatly limits the amplification of any fragments that do not have a correct sequence at their 3 'end. In this way the amplification step also contributes to the purity of the final result of the synthesis process.
    [0034] The present invention also relates to the nucleic acids synthesized by the method described above. The nucleotide sequence of these nucleic acids can be predetermined, imposing the order of polymerization of said nucleotides during the realization of elongation cycles. However, it is conceivable to use the method of the present invention for the synthesis of nucleic acids having random sequences. The synthesis method according to the present invention allows the synthesis of nucleic acids of all sizes, the minimum size of the nucleic acids being nevertheless determined by the minimum size of the initial primers used during the synthesis. Subject to available resources in sufficient quantities and subject to space and favorable conditions, there is no maximum size of nucleic acids synthesizable by the method object of the present invention. In a preferred embodiment of the present invention, it is possible to synthesize nucleic acid fragments having a length of between 3 and 1.109 bases, preferably between 20 and 1.107 bases. The nucleic acids thus synthesized may comprise nucleotide sequences having multiple biological or biotechnological roles.
    [0035] Advantageously, the present invention replaces a certain number of manipulations in the field of molecular biology and genetic engineering, these tedious and repetitive manipulations being carried out usually by hand by experimenters of the art.
    [0036] The use of the method of the present invention allows a significant increase in the performance and productivity of any method involving nucleic acid manipulations. By way of nonlimiting examples, the use of the present invention is particularly advantageous in the following fields: elaboration of genetic constructs, production of interfering RNA molecules, production of DNA or RNA chips, construction of strains or lines cellular, enzymatic engineering, development of protein models, development of biotherapies, development of animal or plant models. The nucleic acids obtained using the method described above can be directly used during molecular biology manipulations known to those skilled in the art. The nucleic acids thus obtained have a degree of purity extremely well suited to direct use without the need for additional processing steps. Alternatively, the nucleic acids synthesized by the process according to the invention of synthesis can undergo complementary modifications aiming for example to circularize the nucleic acid fragments, insert the nucleic acid fragments into expression vectors, insert the fragments of nucleic acids in the genome of living cells, reacting nucleic acid fragments with other chemical entities, or using nucleic acid fragments for catalyzing a reaction.35 Automation The automation of the process the present invention may be carried out by any previously adapted device that can optimize it, in particular by minimizing the duration of an elongation cycle, by maximizing the accuracy of additions, washes and fluid flows and by optimizing the reaction conditions used during the different stages of these cycles. The method according to the present invention allows the synthesis of directly usable nucleic acids without additional purification or assembly steps due to the high purity of the synthesized nucleic acids, regardless of their size. The automation of the process object of the present invention thus has a great industrial and commercial interest. The present invention also relates to any kit for carrying out the process described above, comprising: a reaction medium containing nucleic acid fragments comprising n nucleotides; an enzymatic nucleotide addition reagent; nucleotides or combinations; nucleotides capable of being added by said enzymatic addition reagent - washing solutions and / or buffer for the purification phase - an amplification reaction medium containing: an enzymatic nucleic acid amplification reagent, and nucleotides natural compounds suitable for use with the enzymatic amplification reagent-a user's manual. Different types of kits can be proposed according to the needs of the experimenter. In particular, different initiation primers may be proposed in different kits depending on the sequences to be synthesized. Similarly, different types of kits can be offered depending on whether or not they are used automatically. According to a preferred embodiment the kit for carrying out the preferred embodiment of the method of the present invention comprises: nucleic acid fragments used as synthesis primer. a first attachment support for the nucleic acid fragments comprising n nucleotides; a second attachment support for the added nucleic acid fragments; an addition reaction medium containing: an enzymatic nucleotide addition reagent and nucleotides or combinations of nucleotides capable of being added by the enzymatic addition reagent -washing and / or buffering solutions for the attachment, purification and stalling steps - an amplification reaction medium comprising: an enzymatic reagent of amplification of nucleic acids, and natural nucleotides suitable for use by the enzymatic amplification reagent - instructions for use. The above kit may further comprise: buffer media that are suitable for the attachment of nucleic acid fragments to the first and / or second attachment support, and / or buffer media that are favorable for stalling the fragments of nucleic acids of the first and / or second attachment support.
    [0037] DESCRIPTION OF THE FIGURES The description of an exemplary embodiment of the preferred embodiment of the invention with implementation of attachment supports for immobilizing the nucleic acid fragments during certain steps of the synthesis process will be described hereinafter. reference to the figures in which Figures 1 to 7 show schematically the various steps of the method: Figure 1 immobilization of the starting fragments; Figure 2 the addition of a nucleotide to the immobilized fragments; Figure 3 a washing step and stalling of the added nucleic acid fragments; FIG. 4 the attachment, on a second support, of the added nucleic acid fragments; Figure 5 deprotection of the added nucleic acid fragments; Figure 6 an amplification step; Figure 7 starts a new cycle using the added fragments of the previous cycle; and FIG. 8 shows a possible arrangement scheme of the "reactors" for carrying out the enzyme addition phase and the purification phase of the correct sequence fragments. EXAMPLE Referring to the figures, an elongation cycle of nucleic acid fragments in the synthesis method according to the invention is described below. On a first solid support 1, such as a glass plate, are fixed strands 4 comprising at least three nucleotides. Primers or fragments in the course of elongation 3 of nucleic acids containing Xi + n nucleotides are linked to strands 4 attached to support 1 via hydrogen bonds between their respective bases. The nucleic acid fragment being elongated 3 comprises a free part 33 and an immobilizable part 34 with at least three nucleotides complementary to those of the fixed strands 4 and representing the primer. In the reaction medium, as shown schematically on the right of FIG. 1, nucleic acid fragments immobilized on the first solid support 1 are then obtained. An enzymatic addition step is then carried out by adding a reaction medium containing addition enzymes and reagents 6 comprising at least one nucleotide 7, one end of which is blocked by a protective group 8. As a result, as shown schematically in the right part of FIG. reagents 6 at the free end 33 of the fragments immobilized on the first solid support to give nucleic acid fragments added (that is to say having received at least one nucleotide) protected end, immobilized on the support 1. These fragments of nucleic acids protected and immobilized are referenced 36. There remains, in the reaction medium, either on the support or in the vicinity of said support 1, residues of enzymes, reagents 6, and any buffer solutions, which are then removed by washing according to arrow 3A. After this first washing 3A, are unhooked, according to the arrow 3B, of the support 1 fragments 36 which will give added fragments, protected, free referenced 38 in Figure 3. However, this stall step detaches the support 1 at a time added fragments 38 and initial fragments 3 not added. A second support 2, in this case magnetic beads, coated with a coating 9 formed of proteins such as antibodies, dihydrofolate reductase (DHFR), avidin, streptavidin, is then used, as schematized in FIG. glutathione-stransferase (GST), phosphopeptides (serine oligomers, tyrosine or threonine) or histidine oligomers in the reaction medium containing nucleic acid fragments of correct sequence and fragments of incorrect sequence. This results in a binding by the terminal protecting group 8 to a bonding, on the surface of the beads 2, of the protected correct sequence fragments 38. Initial fragments 3 which have not undergone the enzymatic addition, and therefore do not contain any end with the protective group that can bind to the proteins of the coating 9 of the balls 2, are then easily removed by washing. After this step of efficiently selecting the fragments with the correct sequence, the magnetic beads 2 are separated by changing the conditions of the reaction mixture. For example, a change in pH, an increase in temperature, or the action of a reagent or an electromagnetic field makes it possible to unhook the added fragments from the beads to obtain free unprotected added fragments in the reaction medium ( see Figure 5).
    [0038] The balls 2 covered with the protective groups remaining bound to the coating 9 are then removed from the reaction medium, for example by the action of a magnetic field. FIG. 6 then schematizes an amplification step of the unprotected added fragments 37 having undergone the elongation cycle described until now, under the action of an amplification reaction medium 11 comprising the amplification enzymes as well as nucleotides, for example natural. The number of nucleic acid fragments 37 is then amplified considerably.
    [0039] This amplification step is quite effective because it only amplifies the fragments 37 having undergone the elongation cycle. This further minimizes the use of amplification reagents. No further purification step is then necessary, before completing the synthesis or proceeding to a new cycle i + 1 elongation.
    [0040] A new cycle of elongation can then take place via the same first solid support 1 on which the strands 4 serving to immobilize the fragments 37 are fixed, as shown diagrammatically in FIG. 7. FIG. 8 shows the diagram of an example of elongation chamber, preferably 5 with two separate compartments, in which each elongation cycle according to the present invention is carried out. The first reactor 10, compartment in which the enzymatic addition phase is carried out, contains the first solid support 1 on which the strands 4 are attached, and 10 is connected to a supply device 70 in nucleotides 7 of addition and to a supply device 50 for addition enzyme 5. The second reactor 12, compartment in which the purification phase of the correct synthesis fragments is carried out, is equipped here with an electromagnetic device 15 (electromagnet 21) and is connected to a supply 20 of ball-type supports. The two reactors 10 and 12, separated to allow better purification of the fragments are nevertheless connected to each other and connected to the inputs 13, 14 of the washing solution (s) and to the outlets 15, 16 of waste to be evacuated. The amplification step (s) is (are) also carried out inside the reactor 12. The nucleic acids thus synthesized are recovered at the outlet 17 of the second reactor after the final amplification step. An illustrative example of synthesis of a DNA fragment is described below. The enzyme chosen for carrying out the enzymatic synthesis steps is the deoxynucleotidyl transferase terminal or commercially available TdT (Thermo Scientific). It is also possible to recombinantly produce significant amounts of TdT. The primer used to initiate the synthesis is given below: ## STR1 ## This primer has a restriction site involving cleavage of the sequence by of the arrow in the sequence above. In the case where the sequence to be synthesized also includes a Pst1 site, the initial primer would be modified in a manner.
    [0041] The nucleotides used have at their 5 'end a triphosphate group that promotes their reactivity. They possess one of the four nitrogen bases naturally present in the DNA molecule namely A adenine, T Thymine, C Cytosine or G guanine, and have at their 3 'end a group other than the naturally occurring hydroxyl group and which has the ability to block any subsequent nucleotide addition by TdT and the ability to interact with other molecules or proteins. The synthesis conditions used come from the description of the protocol associated with the TdT enzyme: 50 U of TdT, 200 mM sodium cacodylate, 25 mM Tris-HCl pH 7.2, 8 mM MgCl 2, 0.33 mM ZnSO 4, 0, 2 mM dATP, 2 pmol of primer (Seq No. 1) and 100 μM of protected nucleotide are mixed for a total of 50 μl of reaction volume. The mixture is incubated for 5 min at 37 ° C. Depending on the nature of the protecting group selected, the added nucleotides are deprotected by the action of mild acid such as 50 mM sodium acetate pH 5.5 in the presence of 10 mM MgCl 2 for 15 min at 37 ° C. The deprotection reaction results in destroying the existing binding between the nucleotide and the protecting group as well as any other group possibly associated with the protecting group. According to some preferred embodiments of the invention, this deprotection step can simultaneously release the fragment of an interaction at its 3 'end.
    [0042] The DNA fragments being synthesized are incubated for 10 min at 20 ° C. in a reaction chamber comprising a glass plate on which have been fixed beforehand DNA fragments having the following sequence: 3'-CCCCCCCCCCCCCCGACGTC-5 ' Seq No. 2 The DNA microarray generation techniques were implemented for the attachment by the 3 'end of DNA fragment having the sequence (Seq No. 2). The DNA fragments are thus immobilized in this way.
    [0043] The washing steps are carried out with a solution of 25 mM Tris-HCl pH 7.2 at a rate of 5 μl per second for 30 seconds. The release steps of the DNA fragments are carried out by passing a solution of 25 mM Tris-HCl, pH 7.2 at 95 ° C at a rate of 5 μl per second for 60 seconds. The transfers of the free DNA fragments are carried out by means of a system of valves allowing the flow of 25 mM Tris-HCl pH 7.2, in which the fragments are dissolved, to be conveyed into the second reactor 12. DNA fragments having undergone the enzymatic elongation step using the protected nucleotides are then incubated for 15 min at room temperature in the presence of magnetic beads 2 having on their surface a molecule or protein allowing the interaction with the last added nucleotide. Magnetic beads coated with GST protein are a non-limiting example of the type of beads that can be used. Using a permanent magnet, the magnetic beads 2 carrying the DNA fragments are made static while a flow of 25 mM Tris-HCl, pH 7.2 at a rate of 10 μl per second is applied. at the end of washing for 30 seconds. The amplification step of the DNA fragments is carried out by the enzyme Platinum® Taq DNA Polymerase (Invitrogen) according to the following protocol: 10X buffer provided 1x, dNTP 0.2 mM each nucleotide, MgCl 2 1.5 mM, primer 0.2 μM complementary, 1.0 U polymerase for a total volume of 50 μL. The amplification cycles used are given by the following table: incubation at 94 ° C. for 60 sec, application of 30 amplification cycles with the following steps: denaturation at 94 ° C. for 30 seconds and then pairing at 55 ° C. for 30 sec. After extension to 72 ° C. for 60 seconds per thousand nucleotides to be amplified, a final extension step at 72 ° C. for 5 minutes is added. The primer is chosen according to the state of progress of the synthesis of the DNA fragments. It has a sequence of about 20 nucleotides. The amplification conditions described above are modulated so as to promote a very specific amplification of the fragments able to match exactly with the chosen complementary primer. The size of this complementary primer is also chosen according to the sequence so as to promote the most specific amplification possible.
    [0044] According to the principles set forth by the present invention, the performances of the various steps have been measured and are presented in Table 1 below: Good rates Fragment fragments poor Enzymatic addition 80 ') / 0 20% Purification (Steps 90 `) The broad elimination steps, for example, make it possible to retain 90% of the fragments having a correct sequence (considered as "good") and only 2% of the fragments having the same sequence. an incorrect sequence (considered "bad"). The repetition of the cycles employing these various judiciously associated steps allows the synthesis of long fragments whose final purity is given in Table 2 below (initial primer amount of 2 pmol): Elongation Purification Amplification Purity Cycle Good Bad Good Bad Good Bad Bad Bad 0 9.63E + 11 2.40E + 11 8.67E + 11 4.82E + 09 8.67E + 11 4.82E + 09 99.44% 0.552% 1 6, 93E + 11 1,78E + 11 6,24E + 11 3,57E + 09 6,24E + 11 3,57E + 09 99,43% 0,568% 10 3,60E + 10 9,27E + 9 3,24E + 10 1.86E + 08 3.24E + 10 1.86E-1-08 99.43% 0.568% 50 70870 18224 63783 365 63783 365 99.43% 0.569% 100 4609640 1185337 4148676 23707 4148676 23707 99.43% 0.568% Elongation Purification Amplification Purity Cycle Vouchers Bad Vouchers Bad Vouchers Bad Vouchers Bad 500 1816 467 1634 10 1634 10 99.392% 0.608% 1000 2852 734 2566 15 2566 15 99.419% 0.581% 5000 94719 24356 85247 488 7.67E + 13 4.88E + 09 99.994 % 0.006% 20 Table 2 So despite the inherent imperfection at each step taken separately and despite the presence of fragments failing at various stages of the synthesis, the final result has a purity of more than 99% and is therefore directly usable by the experimenter and this independently of the length of the fragment considered . The results given by this table are presented as examples and may be substantially different if the parameters (presented in Table 1) of good and bad fragment rates generated at each step, taken as parameters, are different.
    [0045] Industrial application The method of the present invention allows the synthesis of nucleic acids without loss of yield, regardless of their length. It allows a substantial improvement in the performance of nucleic acid synthesis compared to existing techniques in particular in terms of simplicity of implementation, synthesis costs, synthesis time, purity of the products obtained and capacity for synthesis. This method can be used for the production of synthetic genes or nucleic acid sequences. It is particularly intended for the synthesis of nucleic acids such as DNA or RNA for purposes of research, development or industrialization in the field of biotechnology or more generally in the broad field of biology.
    权利要求:
    Claims (17)
    [0001]
    REVENDICATIONS1. A process for synthesizing nucleic acids, particularly nucleic acids of great length, comprising at least one nucleic acid fragment elongation cycle, called initial fragments, comprising n (or n-sequence) nucleotides, each cycle being subdivided as follows: d) an enzymatic addition phase of Xi nucleotides at one end of said fragments, X being between 1 and 5, preferably between 1 and 3, i 1 () being the cycle number, to obtain fragments comprising n + Xi nucleotides, called the first phase, e) a purification phase of the fragments having a correct sequence comprising n + Xi nucleotides, called the second phase, f) a possible amplification phase, preferably an enzymatic phase , such as by PCR, fragments having a correct sequence with n + Xi nucleotides, by a multiplying factor Yi, i being the cycle number, Y being between 1 and 4.1019, of 1 to 1.109, referred to as the third phase, each cycle being carried out in a reaction medium compatible with an enzymatic addition and amplification, such as an aqueous medium, the synthesis method also comprising at the end of all the elongation cycles, a final amplification step of a multiplying factor Yf.
    [0002]
    2. The method according to claim 1, characterized in that the purification phase of the correct sequence fragments with n + 1 + nucleotides comprises the removal of the non-added fragments and / or any other unwanted residual reagent.
    [0003]
    3. Process according to claim 1 or 2, characterized in that the amplification phase is a selective amplification of the nucleotide sequence fragments, called correct sequence fragments, multiplying in the reaction medium the fragments having a sequence correct by a multiplicative factor more than 10 times higher, preferably more than 100 times greater, the multiplicative factor of other fragments, called fragments of incorrect sequence, including non-added fragments. 35
    [0004]
    4. Method according to one of claims 1 to 3, characterized in that it comprises several cycles subdivided in the following manner: a) a first phase comprising the following successive steps: - a first attachment step, on a first support, of a first end of nucleic acid fragments initial or in the process of elongation, containing n nucleotides, - a step of adding the reagents necessary for the enzymatic addition, an enzymatic addition step of Xi nucleotides at the second end of said nucleic acid fragments, X may be between 1 and 5, preferably between 1 and 3, i being the number of the ring, a possible step of eliminating the reaction medium from the unwanted reagents, stalling step of said first support of said fragments to n + Xi nucleotides, - a first step of transferring said fragments to n + Xi nucleotides; b) a second phase comprising the following successive steps: a second step of attachment, on a second support, of said fragments with n + Xi nucleotides by their end bearing the xi nucleotides added during the first phase, a step of removing the non-added fragments and non-hooked fragments on the second support; - a stalling step of said n + Xi nucleotide fragments of said second support - a possible step of removing the reaction medium from the unwanted residual reactants; c) an optional amplification phase comprising the following successive steps: a step of adding the reagents necessary for the amplification, a step (optionally composed of substeps allowing the process) of multiplying a multiplying factor Yi of the fragments to n + Xi nucleotides, i being the ring number, Y being between 1 and 4.1010, preferably between 1 and 1.109, a step of transferring the fragments to n + Xi nucleotides.
    [0005]
    5. Method according to claim 4, characterized in that the first support has a surface on which are non-covalently attached strands of nucleic acids to at least three nucleotides, said nucleotides of these strands being complementary nucleotides present at the first end of the initial fragments, so as to immobilize by hydrogen bonds between their respective bases, said first ends of the fragments.
    [0006]
    6. Method according to claim 4 or 5 characterized in that said first and second supports are in the form of glass plate, plate of polymer material, or beads, preferably one or other of these supports , advantageously the second support, having magnetic properties.
    [0007]
    7. Method according to any one of the preceding claims, characterized in that the addition of X nucleotides is effected enzymatically, by means of enzymes capable of polymerizing modified nucleotides without the presence of a template strand.
    [0008]
    8. Process according to claim 7, characterized in that the enzyme is chosen from enzymes of the telomerase family, translational enzymes, RNA polymerase independent matrix or enzymes of the family of terminal deoxynucleotidyl transferases.
    [0009]
    9. Process according to any one of claims 4 to 8, characterized in that the free end of the nucleotide or nucleotides added to the fragments comprises a protective chemical group, to prevent a multiple addition of X nucleotides on the same fragment.
    [0010]
    10. Process according to claim 9, characterized in that the second support is covered with molecules, such as proteins, allowing non-covalent binding between these molecules and said protective chemical group, and thus the immobilization of the added fragments during the second stage of attachment.
    [0011]
    11. Process according to any one of the preceding claims, characterized in that the step of stalling said n + Xi nucleotide fragments from said second support is carried out by modifying the conditions of the reaction medium, such as modifications of the pH, or the temperature, or under the action of electromagnetic radiation if said second medium is a magnetic medium. 35
    [0012]
    12. Method according to any one of claims 4 to 11 characterized in that the first attachment step corresponds to the attachment of the 5 'ends nucleic acid fragments starting, or being elongated, and the second snap step corresponds to the attachment of the 3 'ends of said fragments to n + Xi nucleotides.
    [0013]
    13. The method of claim 12 characterized in that the enzymatic addition is carried out in the direction 5 'to 3'.
    [0014]
    14. Use of the method according to any one of the preceding claims for the production of genes, or synthetic nucleic acid sequences, DNA or RNA.
    [0015]
    15. A kit for carrying out the method according to any one of claims 1 to 13 comprising: a reaction medium containing nucleic acid fragments comprising n 15 nucleotides - an enzymatic nucleotide adduct reagent - nucleotides or combinations of nucleotides capable of being added by said enzymatic addition reagent - washing solutions (13,14) and / or buffer for the purification phase - an amplification reaction medium comprising: an enzymatic reagent for amplification of nucleic acids, and natural nucleotides suitable for use by the enzymatic amplification reagent-a user's manual. 25
    [0016]
    16. Kit for carrying out the method according to any one of claims 4 to 13 comprising: nucleic acid fragments used as synthesis primer. a first support (1) for attaching nucleic acid fragments comprising n nucleotides; a second support (2) for attaching the added nucleic acid fragments; an addition reaction medium containing: an enzymatic reagent; addition of nucleotides and nucleotides or combinations of nucleotides capable of being added by the enzymatic addition reagent of the washing (13,14) and / or buffer solutions for the attachment, purification and stalling steps; an amplification reaction medium comprising: an enzymatic reagent for amplifying nucleic acids, and natural nucleotides that can be used by the enzymatic amplification reagent-a user's manual.
    [0017]
    17. Kit according to claim 16, further comprising: buffer media that are suitable for the attachment of the nucleic acid fragments to the first and / or second attachment support, and / or stalling buffering media. nucleic acid fragments of the first and / or second attachment support.
    类似技术:
    公开号 | 公开日 | 专利标题
    EP3132048B1|2019-12-04|Method for synthesising nucleic acids, in particular long nucleic acids, use of said method and kit for implementing said method
    EP0787209B1|2002-03-20|Method for amplifying nucleic acid sequences by displacement using chimeric primers
    EP3570972B1|2021-08-18|Methods and reagents for synthesising polynucleotide molecules
    JP2021524246A|2021-09-13|Polynucleotide Synthesis Methods, Systems, and Kits
    JP2021529549A|2021-11-04|Polynucleotide Synthesis Methods, Kits, and Systems
    JP2017537657A|2017-12-21|Target sequence enrichment
    JP2021529548A|2021-11-04|Polynucleotide Synthesis Methods, Kits, and Systems
    Kong et al.2016|Generation of Synthetic Copolymer Libraries by Combinatorial Assembly on Nucleic Acid Templates
    Zaher et al.2004|T7 RNA polymerase mediates fast promoter-independent extension of unstable nucleic acid complexes
    KR20200004335A|2020-01-13|How to trap and barcode separate biological units in a hydrogel
    WO2021128441A1|2021-07-01|Controlled strand-displacement for paired-end sequencing
    CA2868926C|2021-05-04|Modified oligonucleotides comprising thiol functions and the use of same for the detection of nucleic acids
    JP2021529551A|2021-11-04|Polynucleotide Synthesis Methods, Kits, and Systems
    EP2464747B1|2019-04-10|Method for detection of circularized dna and use of the method for detection of mutations
    JP6069314B2|2017-02-01|Large-scale synthesis method of long nucleic acid molecules
    TW201840855A|2018-11-16|Compositions and methods for template-free enzymatic nucleic acid synthesis
    WO2021104514A1|2021-06-03|Enzymatic synthesis of oligonucleotides
    US10864549B2|2020-12-15|Half-coating method for nanoparticles
    Kuwahara2014|Progress in chemically modified nucleic acid aptamers
    Zhukov et al.2019|Methods for Molecular Evolution of Polymerases
    AU2019445584A1|2022-01-20|Single-channel sequencing method based on self-luminescence
    WO2021207158A1|2021-10-14|Reusable initiators for synthesizing nucleic acids
    FR2809105A1|2001-11-23|MODIFIED AMPLIFIER PRIMERS AND USES THEREOF
    同族专利:
    公开号 | 公开日
    JP2017514465A|2017-06-08|
    KR20160138581A|2016-12-05|
    CA2945898A1|2015-10-22|
    US20210130863A1|2021-05-06|
    US20190300923A1|2019-10-03|
    EP3132048B1|2019-12-04|
    EP3620526A1|2020-03-11|
    IL248234D0|2016-11-30|
    US10913964B2|2021-02-09|
    FR3020071B1|2017-12-22|
    AU2015248673A1|2016-11-03|
    AU2015248673B2|2019-05-23|
    IL248234A|2020-06-30|
    JP6783145B2|2020-11-11|
    US20190264248A1|2019-08-29|
    US10837040B2|2020-11-17|
    WO2015159023A1|2015-10-22|
    EP3132048A1|2017-02-22|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US5808045A|1994-09-02|1998-09-15|Andrew C. Hiatt|Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides|
    WO2000060072A1|1999-04-06|2000-10-12|Medical Biosystems Ltd.|Polynucleotide synthesis using a processing enzyme|
    WO2005059096A2|2003-12-10|2005-06-30|Massachusetts Institute Of Technology|Methods for high fidelity production of long nucleic acid molecules with error control|
    US4772691A|1985-06-05|1988-09-20|The Medical College Of Wisconsin, Inc.|Chemically cleavable nucleotides|
    US5262530A|1988-12-21|1993-11-16|Applied Biosystems, Inc.|Automated system for polynucleotide synthesis and purification|
    US5047524A|1988-12-21|1991-09-10|Applied Biosystems, Inc.|Automated system for polynucleotide synthesis and purification|
    CA2044616A1|1989-10-26|1991-04-27|Pepi Ross|Dna sequencing|
    US5516664A|1992-12-23|1996-05-14|Hyman; Edward D.|Enzymatic synthesis of repeat regions of oligonucleotides|
    US5436143A|1992-12-23|1995-07-25|Hyman; Edward D.|Method for enzymatic synthesis of oligonucleotides|
    FR2703052B1|1993-03-26|1995-06-02|Pasteur Institut|New method of nucleic acid sequencing.|
    US5656745A|1993-09-17|1997-08-12|Gilead Sciences, Inc.|Nucleotide analogs|
    AU1436995A|1993-12-30|1995-07-17|Chemgenes Corporation|Synthesis of propargyl modified nucleosides and phosphoramidites and their incorporation into defined sequence oligonucleotides|
    US6232465B1|1994-09-02|2001-05-15|Andrew C. Hiatt|Compositions for enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides|
    US5990300A|1994-09-02|1999-11-23|Andrew C. Hiatt|Enzyme catalyzed template-independent creation of phosphodiester bonds using protected nucleotides|
    US5872244A|1994-09-02|1999-02-16|Andrew C. Hiatt|3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds|
    US6214987B1|1994-09-02|2001-04-10|Andrew C. Hiatt|Compositions for enzyme catalyzed template-independent formation of phosphodiester bonds using protected nucleotides|
    US5763594A|1994-09-02|1998-06-09|Andrew C. Hiatt|3' protected nucleotides for enzyme catalyzed template-independent creation of phosphodiester bonds|
    US5917031A|1996-04-19|1999-06-29|Taiko Pharmaceutical Co., Ltd.|Method of synthesizing polydeoxyribonucleotides|
    JP2002537858A|1999-03-10|2002-11-12|エーエスエムサイエンティフィック，インコーポレイテッド|Methods for direct sequencing of nucleic acids|
    GB0013276D0|2000-06-01|2000-07-26|Amersham Pharm Biotech Uk Ltd|Nucleotide analogues|
    EP1790736A3|2000-10-06|2007-08-15|The Trustees Of Columbia University In The City Of New York|Massive parallel method for decoding DNA and RNA|
    WO2002079516A1|2001-03-30|2002-10-10|Applera Corporation|Nucleic acid analysis using non-templated nucleotide addition|
    GB0129012D0|2001-12-04|2002-01-23|Solexa Ltd|Labelled nucleotides|
    US7057026B2|2001-12-04|2006-06-06|Solexa Limited|Labelled nucleotides|
    SI3363809T1|2002-08-23|2020-08-31|Illumina Cambridge Limited|Modified nucleotides for polynucleotide sequencing|
    US7504215B2|2002-07-12|2009-03-17|Affymetrix, Inc.|Nucleic acid labeling methods|
    CA2506797C|2002-11-22|2009-02-10|F.Hoffmann-La Roche Ag|Detectable labeled nucleoside analogs and methods of use thereof|
    DE60335144D1|2003-02-05|2011-01-05|Ge Healthcare Bio Sciences|nucleic acid amplification|
    US7407757B2|2005-02-10|2008-08-05|Population Genetics Technologies|Genetic analysis by sequence-specific sorting|
    US7544794B1|2005-03-11|2009-06-09|Steven Albert Benner|Method for sequencing DNA and RNA by synthesis|
    US8212020B2|2005-03-11|2012-07-03|Steven Albert Benner|Reagents for reversibly terminating primer extension|
    US7550264B2|2005-06-10|2009-06-23|Datascope Investment Corporation|Methods and kits for sense RNA synthesis|
    WO2008042067A2|2006-09-28|2008-04-10|Illumina, Inc.|Compositions and methods for nucleotide sequencing|
    US7858772B2|2006-12-22|2010-12-28|Roche Molecular Systems, Inc.|Compounds and methods for synthesis and purification of oligonucleotides|
    JP5745842B2|2007-06-19|2015-07-08|ストラトス ゲノミクス インコーポレイテッド|High throughput nucleic acid sequencing by extension|
    US8034923B1|2009-03-27|2011-10-11|Steven Albert Benner|Reagents for reversibly terminating primer extension|
    US8674086B2|2010-06-25|2014-03-18|Intel Corporation|Nucleotides and oligonucleotides for nucleic acid sequencing|
    AU2013232131B2|2012-03-13|2018-09-20|Swift Biosciences, Inc.|Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase|
    US8808989B1|2013-04-02|2014-08-19|Molecular Assemblies, Inc.|Methods and apparatus for synthesizing nucleic acids|
    US9279149B2|2013-04-02|2016-03-08|Molecular Assemblies, Inc.|Methods and apparatus for synthesizing nucleic acids|
    FR3025201B1|2014-09-02|2018-10-12|Dna Script|MODIFIED NUCLEOTIDES FOR THE SYNTHESIS OF NUCLEIC ACIDS, A KIT COMPRISING SUCH NUCLEOTIDES AND THEIR USE FOR GENERATING SYNTHETIC NUCLEIC ACID GENES OR SEQUENCES|FR3047251A1|2016-02-02|2017-08-04|Dna Script|INSTALLATION FOR IMPLEMENTING A PROCESS FOR THE ENZYMATIC SYNTHESIS OF NUCLEIC ACIDS|
    FR3052462A1|2016-06-14|2017-12-15|Dna Script|POLYMERASE DNA VARIANTS OF THE POLX FAMILY|
    GB2559117B|2017-01-19|2019-11-27|Oxford Nanopore Tech Ltd|Double stranded polynucleotide synthesis method, kit and system|
    ES2897552T3|2017-09-20|2022-03-01|Pasteur Institut|DNA polymerase theta mutants, methods for producing these mutants, and their uses|
    AU2020281709A1|2019-05-28|2021-12-16|Centre National De La Recherche Scientifique|Variants of terminal deoxynucleotidyl transferase and uses thereof.|
    CA3087714A1|2018-01-08|2019-07-11|Dna Script|Variants of terminal deoxynucleotidyl transferase and uses thereof|
    WO2020036654A2|2018-04-27|2020-02-20|Arizona Board Of Regents On Behalf Of Arizona State University|Highly knotted molecular topologies from single-stranded nucleic acids|
    US20210332351A1|2018-07-23|2021-10-28|Dna Script|Massively Parallel Enzymatic Synthesis of Nucleic Acid Strands|
    SG11202104601PA|2018-11-14|2021-06-29|Dna Script|Terminal deoxynucleotidyl transferase variants and uses thereof|
    WO2020120442A2|2018-12-13|2020-06-18|Dna Script|Direct oligonucleotide synthesis on cells and biomolecules|
    JP2022515912A|2019-01-03|2022-02-22|ディーエヌエー スクリプト|One-pot synthesis of oligonucleotide sets|
    WO2020165137A1|2019-02-12|2020-08-20|Dna Script|Efficient product cleavage in template-free enzymatic synthesis of polynucleotides.|
    EP3744854A1|2019-05-28|2020-12-02|DNA Script|Variants of terminal deoxynucleotidyl transferase and uses thereof|
    WO2021018919A1|2019-07-30|2021-02-04|Dna Script|Template-free enzymatic synthesis of polynucleotides using poly and poly polymerases|
    WO2021018921A1|2019-08-01|2021-02-04|Dna Script|Increasing long-sequence yields in template-free enzymatic synthesis of polynucleotides.|
    WO2021048142A1|2019-09-09|2021-03-18|Dna Script|Template-free enzymatic polynucleotide synthesis using photocleavable linkages|
    WO2021058438A1|2019-09-23|2021-04-01|Dna Script|Increasing long-sequence yields in template-free enzymatic synthesis of polynucleotides|
    WO2021094251A1|2019-11-13|2021-05-20|Dna Script|High efficiency template-free enzymatic synthesis of polynucleotides|
    WO2021116270A1|2019-12-12|2021-06-17|Dna Script|Chimeric terminal deoxynucleotidyl transferases for template-free enzymatic synthesis of polynucleotides|
    WO2021122539A1|2019-12-16|2021-06-24|Dna Script|Template-free enzymatic polynucleotide synthesis using dismutationless terminal deoxynucleotidyl transferase variants|
    WO2021170524A1|2020-02-25|2021-09-02|Dna Script|Method and apparatus for enzymatic synthesis of polynucleotides|
    WO2021213903A1|2020-04-20|2021-10-28|Dna Script|Terminal deoxynucleotidyl transferase variants and uses thereof|
    WO2021254934A1|2020-06-16|2021-12-23|Dna Script|Systems, apparatus and kits for enzymatic polynucleotide synthesis|
    WO2022013094A1|2020-07-15|2022-01-20|Dna Script|Massively parallel enzymatic synthesis of polynucleotides|
    法律状态:
    2016-04-21| PLFP| Fee payment|Year of fee payment: 3 |
    2017-04-19| PLFP| Fee payment|Year of fee payment: 4 |
    2017-09-15| TP| Transmission of property|Owner name: DNA SCRIPT, FR Effective date: 20170808 |
    2017-09-15| CA| Change of address|Effective date: 20170808 |
    2017-09-15| CD| Change of name or company name|Owner name: DNA SCRIPT, FR Effective date: 20170808 |
    2018-04-20| PLFP| Fee payment|Year of fee payment: 5 |
    2019-04-16| PLFP| Fee payment|Year of fee payment: 6 |
    2020-04-10| PLFP| Fee payment|Year of fee payment: 7 |
    2021-04-19| PLFP| Fee payment|Year of fee payment: 8 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1453455A|FR3020071B1|2014-04-17|2014-04-17|PROCESS FOR THE SYNTHESIS OF NUCLEIC ACIDS, IN PARTICULAR LARGE NUCLEIC ACIDS, USE OF THE METHOD AND KIT FOR IMPLEMENTING THE METHOD|FR1453455A| FR3020071B1|2014-04-17|2014-04-17|PROCESS FOR THE SYNTHESIS OF NUCLEIC ACIDS, IN PARTICULAR LARGE NUCLEIC ACIDS, USE OF THE METHOD AND KIT FOR IMPLEMENTING THE METHOD|
    AU2015248673A| AU2015248673B2|2014-04-17|2015-04-15|Method for synthesising nucleic acids, in particular long nucleic acids, use of said method and kit for implementing said method|
    US15/304,701| US10913964B2|2014-04-17|2015-04-15|Method for synthesizing nucleic acids, in particular long nucleic acids, use of said method and kit for implementing said method|
    EP19195271.2A| EP3620526A1|2014-04-17|2015-04-15|Method for synthesising nucleic acids, in particular extended-length nucleic acids, use of the method and kit for implementing said method|
    CA2945898A| CA2945898A1|2014-04-17|2015-04-15|Method for synthesising nucleic acids, in particular long nucleic acids, use of said method and kit for implementing said method|
    EP15725739.5A| EP3132048B1|2014-04-17|2015-04-15|Method for synthesising nucleic acids, in particular long nucleic acids, use of said method and kit for implementing said method|
    PCT/FR2015/051022| WO2015159023A1|2014-04-17|2015-04-15|Method for synthesising nucleic acids, in particular long nucleic acids, use of said method and kit for implementing said method|
    KR1020167032133A| KR20160138581A|2014-04-17|2015-04-15|Method for synthesising nucleic acids, in particular long nucleic acids, use of said method and kit for implementing said method|
    JP2016562483A| JP6783145B2|2014-04-17|2015-04-15|Methods for Synthesizing Nucleic Acids, Especially Long Nucleic Acids, Use of the Methods, and Kits for Implementing the Methods|
    IL248234A| IL248234A|2014-04-17|2016-10-06|Method for synthesising nucleic acids, in particular long nucleic acids, use of said method and kit for implementing said method|
    US16/216,857| US10837040B2|2014-04-17|2018-12-11|Method for synthesizing nucleic acids, in particular long nucleic acids, use of said method and kit for implementing said method|
    US17/070,707| US20210130863A1|2014-04-17|2020-10-14|Method for Synthesizing Nucleic Acids, in particular Long Nucleic Acids, Use of Said Method and Kit for Implementing Said Method|
    [返回顶部]